852 860
Obtaining funding:
None.
Administrative, technical, or material support:
Nguyen, Ross, Kane, Pollack,
Davis, Feng, Klein.
Supervision:
Nguyen, Klein.
Other:
None.
Financial disclosures:
Paul L. Nguyen certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents filed,
received, or pending), are the following: Nguyen has consulted for
Medivation, GenomeDx, Ferring, Nanobiotix and Dendreon. Nguyen has
received research funding from Astellas. Feng has consulted for
Medivation and GenomeDx. Martin has received personal fees from
Via Oncology. Ross has consulted for GenomeDx Biosciences. Trock has
consulted for Champions Oncology and GenomeDx Biosciences. Klein
has consulted for GenomeDx Biosciences. Kane has received research
grant from GenomeDx Biosciences. Davis has received research grant
from GenomeDx Biosciences. Haddad, Deheshi, Chelliserry, Ong, Buerki,
Aranes, Kolisnik, Margrave, Yousefi, Choeurng, and Davicioni are
employees of GenomeDx Biosciences.
Funding/Support and role of the sponsor:
GenomeDx Biosciences assisted
with the design and concept of the study, collection of the data,
management of the data, analysis, and interpretation of the data.
Acknowledgments:
Funding sources included: The Wood Foundation,
Freeman Family, Fitz’s Cancer Warriors, David and Cynthia Chapin, Hugh
Simons in honor of Frank and Anne Simons, The Campbell Family in
Honor of Joan Campbell, Scott Forbes and Gina Ventre Fund, the Baker
Family, Prostate Cancer Foundation, and a Grant from an Anonymous
Family Foundation.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.05.009 .References
[1]
Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recur- rence of prostate cancer. Curr Opin Urol 2005;15:187–95.[2]
Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreat- ment of prostate cancer. Eur Urol 2014;65:1046–55.[3]
Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) 2016;39:97–106.
[4]
Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8:e66855.[5]
Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190:2047–53.
[6]
Ross AE, Johnson MH, Yousefi K, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural his- tory cohort of intermediate- and high-risk men. Eur Urol 2016;69:157–65.[7]
Glass AG, Leo MC, Haddad Z, et al. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community based health care setting. J Urol 2016;195:1748–53.
[8]
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015;67:326–33.[9]
Knudsen BS, Kim HL, Erho N, et al. Application of a clinical whole- transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens. J Mol Diagn 2016;18: 395–406.
[10]
Lee HJ, Yousefi K, Haddad Z, et al. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Res Reports Urol 2016;8:77–84.[11]
Klein EA, Haddad Z, Yousefi K, et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology 2016;90:148–52.
[12]
Nguyen PL, Martin NE, Choeurng V, et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis 2017;20:186–92.
[13]
Lockstone HE. Exon array data analysis using Affymetrix power tools and R statistical software. Brief Bioinform 2011;12:634–44.
[14]
Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A single-sample microarray normalization method to facilitate per- sonalized-medicine workflows. Genomics 2012;100:337–44.
[15]
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw 2016;14:19–30.
[16]
Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease re- currence after radical prostatectomy. J Urol 2005;173:1938–42.
[17]
Firth D. Bias reduction of maximum likelihood estimates. Biome- trika 1993;80:27.[18]
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337–44.
[19]
Fine JP, Gray RJ. A proportional hazards model for the subdistribu- tion of a competing risk. J Am Stat Assoc 1999;94:496.[20]
Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008;8:53.
[21]
Vickers AJ, Sjoberg DD. Guidelines for reporting of statistics in European urology. Eur Urol 2015;67:181–7.
[22]
Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytor- eduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972–8.
[23]
Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:320–7.[24]
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.
[25]
Prostate Cancer: Summary from ASCO 2015. Can Urol Assoc J 2015;9:S162–4.
[26]
Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86: 848–53.[27]
Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014;192:409–14.
[28]
Klein EA, Santiago-Jime´nez M, Yousefi K, et al. Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential. J Urol 2017;197:122–8.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 4 5 – 8 5 2
852